Prophylactic Cannabinoid Administration Blocks the Development of Paclitaxel-Induced Neuropathic Nociception during Analgesic Treatment and following Cessation of Drug Delivery by Elizabeth J Rahn et al.
MOLECULAR PAIN
Rahn et al. Molecular Pain 2014, 10:27
http://www.molecularpain.com/content/10/1/27RESEARCH Open AccessProphylactic cannabinoid administration blocks
the development of paclitaxel-induced
neuropathic nociception during analgesic
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Background: Chemotherapeutic treatment results in chronic pain in an estimated 30-40 percent of patients. Limited
and often ineffective treatments make the need for new therapeutics an urgent one. We compared the effects of
prophylactic cannabinoids as a preventative strategy for suppressing development of paclitaxel-induced nociception.
The mixed CB1/CB2 agonist WIN55,212-2 was compared with the cannabilactone CB2-selective agonist AM1710,
administered subcutaneously (s.c.), via osmotic mini pumps before, during, and after paclitaxel treatment.
Pharmacological specificity was assessed using CB1 (AM251) and CB2 (AM630) antagonists. The impact of chronic drug
infusion on transcriptional regulation of mRNA markers of astrocytes (GFAP), microglia (CD11b) and cannabinoid
receptors (CB1, CB2) was assessed in lumbar spinal cords of paclitaxel and vehicle-treated rats.
Results: Both WIN55,212-2 and AM1710 blocked the development of paclitaxel-induced mechanical and cold
allodynia; anti-allodynic efficacy persisted for approximately two to three weeks following cessation of drug delivery.
WIN55,212-2 (0.1 and 0.5 mg/kg/day s.c.) suppressed the development of both paclitaxel-induced mechanical and cold
allodynia. WIN55,212-2-mediated suppression of mechanical hypersensitivity was dominated by CB1 activation whereas
suppression of cold allodynia was relatively insensitive to blockade by either CB1 (AM251; 3 mg/kg/day s.c.) or CB2
(AM630; 3 mg/kg/day s.c.) antagonists. AM1710 (0.032 and 3.2 mg/kg /day) suppressed development of mechanical
allodynia whereas only the highest dose (3.2 mg/kg/day s.c.) suppressed cold allodynia. Anti-allodynic effects of
AM1710 (3.2 mg/kg/day s.c.) were mediated by CB2. Anti-allodynic efficacy of AM1710 outlasted that produced by
chronic WIN55,212-2 infusion. mRNA expression levels of the astrocytic marker GFAP was marginally increased by
paclitaxel treatment whereas expression of the microglial marker CD11b was unchanged. Both WIN55,212-2
(0.5 mg/kg/day s.c.) and AM1710 (3.2 mg/kg/day s.c.) increased CB1 and CB2 mRNA expression in lumbar spinal
cord of paclitaxel-treated rats in a manner blocked by AM630.
Conclusions and implications: Cannabinoids block development of paclitaxel-induced neuropathy and protect
against neuropathic allodynia following cessation of drug delivery. Chronic treatment with both mixed CB1/CB2 and
CB2 selective cannabinoids increased mRNA expression of cannabinoid receptors (CB1, CB2) in a CB2-dependent fashion.
Our results support the therapeutic potential of cannabinoids for suppressing chemotherapy-induced neuropathy in
humans.
Keywords: Cannabinoid, CB1, CB2, Chemotherapy, Cold allodynia, Mechanical allodynia, Osmotic mini pump, Paclitaxel* Correspondence: hohmanna@indiana.edu
1Neuroscience and Behavior Program, Department of Psychology, University
of Georgia, Athens, GA, USA
2Program in Neuroscience, Indiana University, Bloomington, IN, USA
Full list of author information is available at the end of the article
© 2014 Rahn et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Rahn et al. Molecular Pain 2014, 10:27 Page 2 of 19
http://www.molecularpain.com/content/10/1/27Background
Cannabinoids attenuate or, in some cases, prevent pain
associated with surgery [1], inflammation [2], internal
organs [3], and neuropathies (for review see [4]). Neuro-
pathic pain is associated with abnormal changes in the
peripheral and/or central nervous system resulting in
non-adaptive, chronic pain. Clinical manifestations of
neuropathic pain are notoriously unresponsive to
traditional analgesics. Chemotherapeutic treatment
with antineoplastic agents, while effective at eliminat-
ing harmful malignancies, is also associated with
severe side effects. Of these side effects, emesis, alope-
cia, and myelosuppression have received the spotlight;
however, a new front runner has recently emerged.
Neuropathic pain associated with chemotherapeutic
treatment is dose-limiting and a major factor influen-
cing discontinuation of treatment [5,6]. Chemother-
apy-induced neuropathy is positively correlated with
cumulative chemotherapeutic dose [7], and affected
patients are more likely to experience other neuropa-
thies [8]. An aging US population, coupled with diag-
nostic and medical advances in cancer treatment,
means that more cancer survivors will be impacted by,
and living longer with, chemotherapy-induced neuropathy.
Thus, identification of prophylactic treatments that block
development of chemotherapy-induced neuropathy repre-
sents an urgent medical need.
Chemotherapeutic agents are divided into three mech-
anistically distinct classes. These classes include the vinca
alkaloids, platinum-derived agents, and taxanes. Taxanes
(e.g., paclitaxel, docetaxel) produce antineoplastic effects
by stabilizing microtubules through binding to β-tubulin,
thereby disrupting normal cell mitosis and triggering
the mitochondrial apoptosis pathway [9]. Paclitaxel is a
preferred agent for treatment of ovarian, breast, and
lung cancers; however, a high percentage of patients
experience neuropathic pain – a type of pain poorly
treated with available drugs [10]. Mechanisms under-
lying development of paclitaxel-induced neuropathy
remain incompletely understood but may involve changes
in glial activation [11,12].
Cannabinoid agonists suppress paclitaxel-induced neuro-
pathic nociception in animal models through activation
of both CB1 [13] and CB2 [14-16] cannabinoid receptor
subtypes. Our laboratory first demonstrated CB2 receptor-
mediated suppression of neuropathic allodynia induced by
chemotherapeutic treatment with vincristine [17], pacli-
taxel [14,18], and cisplatin [15]. Previous prophylactic
treatment strategies with cannabinoids in a traumatic
nerve injury model demonstrated that pre-emptive can-
nabinoids produced greater antinociception relative to
post-injury treatment [19]. Here we investigate the
therapeutic efficacy of prophylactically administered
WIN55,212-2, a mixed cannabinoid (CB1/CB2) agonist,and AM1710, a CB2-preferring agonist, on the develop-
ment of chemotherapy-induced neuropathy in the paclitaxel
model. Osmotic mini pumps were used to continuously
infuse cannabinoids before, during, and after paclitaxel
treatment, to emulate a prophylactic analgesic strategy
achievable in clinical oncology settings. We compared
development of mechanical and cold allodynia, both
common clinical manifestations of paclitaxel-induced
neuropathy [10,20]. We hypothesized that chronic
prophylactic cannabinoid infusion would produce sus-
tained suppression of paclitaxel-induced behavioral
sensitization to mechanical and cold stimulation. Fur-
thermore, we evaluated whether long-term transcrip-
tional changes in mRNA markers of astrocytes (GFAP),
microglia (CD11b), and cannabinoid receptors (CB1,




Paclitaxel-treated animals showed reduced sensitivity
to heat on day 6 (F1,10 = 20.745, P < 0.01; Figure 1a),
but not at subsequent time points (P > 0.16), while
the same animals developed hypersensitivity to mechan-
ical stimulation (i.e., mechanical allodynia) (F1,10 = 6.191,
P < 0.05; Figure 1b). Based upon these results, animals
implanted with osmotic pumps were evaluated for
responsiveness to mechanical and cold stimulation
only.
Osmotic mini pump dispersion volume was calculated
by subtracting the fill volume from the residual volume
in the pump reservoir following pump removal (day 22).
The pump dispersion volume differed between groups
in which drugs were dissolved in the DMSO:PEG400
vehicle (F19,180 = 2.213, P < 0.01). Post-hoc analysis revealed
that pump dispersion volume for the Taxol-WIN55,212-2
(1 mg/kg/day s.c.) group was less than half (< 43%) of other
groups dissolved in the same vehicle. No other differences
were found. Mechanical withdrawal thresholds did not
differ between either the right or left paw on any given
day for animals tested up to 20 (P > 0.98) or 50 (P > 0.71)
days post-chemotherapy treatment; therefore, withdrawal
thresholds are presented as the mean of duplicate
measurements, averaged across paws. Two dependent
measures for cold allodynia were evaluated: percentage
of paw withdrawals and duration of paw withdrawal.
Duration of paw withdrawal in response to topical acetone
application is a reported measure of cold allodynia [21-23].
However, we found this measure highly variable in rat sub-
jects (data not shown) and consequently only the percent-
age of paw withdrawals is reported here. Percentage of paw
withdrawals to cold stimulation did not differ between
either paw on any given day for animals tested up to 21
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Figure 1 Paclitaxel induces mechanical allodynia without producing hypersensitivity to heat. a. Paclitaxel treatment produced transient
heat hypoalgesia but no long-term changes in paw withdrawal latencies to heat whereas b. the same animals developed mechanical allodynia.
Inj indicates days when injections of paclitaxel or cremophor vehicle occurred. Taxol; paclitaxel. *P < 0.05, **P <0.01 vs. Cremophor Vehicle, (ANOVA).
N = 6 per group.
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of duplicate measurements averaged across paws.
To control for any possible effects associated with the
vehicle used to dissolve cannabinoids (DMSO:PEG 400
in a 1:1 ratio), a subset of animals treated with either
paclitaxel or cremophor received saline in their osmotic
mini pumps. No differences were detected between
paclitaxel-treated animals that received vehicle (DMSO:
PEG 400; n = 14) or saline (n = 4) in any behavioral par-
ameter assessed (i.e., mechanical threshold, cold with-
drawal frequency, and locomotor activity). Similarly, no
differences were noted between cremophor-treated ani-
mals receiving chronic infusions of vehicle (DMSO:PEG
400; n = 8) or saline (n = 4). Therefore, vehicle and saline
groups were combined for each condition and are referred
to as the Taxol-vehicle group and cremophor-vehicle
group, respectively.
Body weight
Body weight did not differ between paclitaxel- or
cremophor-treated animals receiving infusions of vehicle
(P = 0.69; Figure 2a). Moreover, no differences in body
weight were observed between paclitaxel-treated ani-
mals receiving either vehicle or saline (data not shown).
However, cremophor-treated animals receiving saline
infusions exhibited greater weight gain on days 14–21
(F12,204 = 8.455, P < 0.001, P < 0.05 for each day) relative
to those receiving vehicle.
Paclitaxel-treated animals receiving infusions of WIN55,
212-2 (0.1 mg/kg/day s.c.) showed greater weight gain
over the study (F68,935 = 3.932, P < 0.001; P < 0.05 for
each comparison) relative to other groups (F4,55 = 2.627,
P < 0.05; Figure 2a). Body weight did not differ in
paclitaxel-treated animals receiving AM1710 (3.2, 0.32,
and 0.032 mg/kg/day s.c.) (P > 0.86; Figure 2b) or eitherantagonist (P > 0.93; Figure 3a). Neither of the agonists
altered weight gain relative to vehicle in cremophor-
treated groups (P = 0.137; data not shown).
Effects of prophylactic WIN55,212-2 and AM1710
treatment on paclitaxel-evoked mechanical allodynia
Anti-allodynic effects of the mixed CB1/CB2 agonist
WIN55,212-2
Paclitaxel-treated animals receiving vehicle infusions
developed mechanical allodynia relative to cremophor-
treated counterparts; mechanical allodynia was appar-
ent on day 2 and persisted until the final test day prior
to pump removal (day 20) (F48,660 = 3.880, P < 0.001;
P < 0.01 for each comparison; Figure 2c). WIN55,212-2
(0.1 mg/kg/day s.c.) produced a transient antinociceptive
effect prior to paclitaxel treatment on day −2 (P < 0.05);
this antinociceptive effect was observed relative to
paclitaxel-treated groups receiving either vehicle or
WIN55,212-2 (1.0 mg/kg/day s.c.). WIN55,212-2 (0.5 mg/
kg/day s.c.) blocked development of paclitaxel-induced
mechanical allodynia (F4,55 = 32.964, P < 0.001; Figure 2c)
and normalized mechanical thresholds relative to the
Taxol-vehicle group at all time points (P < 0.05 for each
comparison). WIN55,212-2 (0.1 mg/kg/day s.c.) also sup-
pressed the development of paclitaxel-evoked mechanical
allodynia over the time course corresponding to drug
delivery (P < 0.05 for each comparison) but failed to
normalize thresholds relative to cremophor-vehicle levels.
Anti-allodynic effects of the CB2 agonist AM1710
AM1710 (3.2 and 0.032 mg/kg/day s.c.) blocked de-
velopment of paclitaxel-evoked mechanical allodynia
(F4,59 = 41.988, P < 0.001; Figure 2d) over the time course
corresponding to drug delivery (F48,708 = 5.186, P < 0.001;




Figure 2 The mixed CB1/CB2 agonist WIN55,212-2 and the CB2-preferring agonist AM1710 suppressed development of paclitaxel-
induced mechanical and cold allodynia. a. WIN55,212-2 (0.1 mg/kg/day s.c.) increased whereas b. AM1710 did not alter body weight in
paclitaxel-treated animals. Mechanical and cold allodynia were suppressed by WIN55,212-2 (0.1 and 0.5 mg/kg/day s.c.; c. and e., respectively) and
AM1710 (0.032 and 3.2 mg/kg/day s.c.; d. and f., respectively). *P < 0.05, **P <0.01, ***P <0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P < 0.01, ###P
<0.001 vs. Taxol-Vehicle, xP < 0.05 vs. Taxol-Agonist (high dose), +P < 0.05, ++P < 0.01 vs. Taxol-Agonist (middle dose), $P < 0.05, vs. Taxol-Agonist
(low dose), βP < 0.05, ββP < 0.01, βββP < 0.001 Taxol-Agonist (middle and low doses) vs. Taxol-Vehicle,⊥⊥P < 0.01, ⊥⊥⊥P < 0.001 Taxol-Agonist (high
and low doses) vs. Taxol-Vehicle, αP < 0.05 Taxol-Agonist (all doses) vs. Taxol-Vehicle, ϕϕϕP <0.001 vs. Taxol-Agonist (middle and low doses). The
first drug listed indicates assignment to cremophor or paclitaxel (Taxol) treatment. The second drug indicates drug administered via osmotic mini
pump chronic infusion. Day numbers reference days post-chemotherapeutic treatment (i.e., negative days indicate days prior to chemotherapeutic
treatment). Surgery indicates the day (day −6) on which osmotic mini pumps were implanted subcutaneously. (ANOVA; Dunnett and Tukey
post-hoc tests). N = 8–18 per group.
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relative to the Taxol-vehicle group beginning on day 4
and this effect was maintained for the duration of the study
(P < 0.05 for each comparison). The high dose of AM1710
(3.2 mg/kg/day s.c.) preferentially increased mechanical
paw withdrawal thresholds relative to the middle dose
(0.32 mg/kg/day s.c.) from days 12–20 (P < 0.05 for each
comparison). Moreover, AM1710 (3.2 mg/kg/day s.c)
normalized paw withdrawal thresholds in paclitaxel-
treated animals to those observed in the cremophor-
vehicle group at all time points.Effects of prophylactic WIN55,212-2 and AM1710
treatment on paclitaxel-evoked cold allodynia
Anti-allodynic effects of the mixed CB1/CB2 agonist
WIN55,212-2
Paclitaxel-induced cold allodynia developed by day 5
and was stable until the final test day associated with
drug delivery (day 21) (F20,275 = 7.197, P < 0.001; P < 0.05
for each comparison; Figure 2e). The middle and low
doses of WIN55,212-2 (0.5 and 0.1 mg/kg/day s.c.)
blocked development of cold allodynia in paclitaxel-
treated animals (F4,55 = 11.428, P < 0.001, P < 0.05 for
ab
c
Figure 3 Neither the CB1 antagonist AM251 nor the CB2
antagonist AM630 altered paclitaxel-induced mechanical or
cold allodynia. a. No changes in body weight, responsiveness to
b. mechanical, or c. cold stimulation were observed in paclitaxel-treated
animals receiving AM630 (3 mg/kg/day s.c.) or AM251 (3 mg/kg/day s.c.)
relative to Taxol-vehicle animals. *P < 0.05, **P < 0.01, ***P <0.001
vs. Cremophor-Vehicle, ^P < 0.05, ^^P < 0.01, ^^^P < 0.001
Taxol-AM630 (3 mg/kg/day s.c.) and Taxol-AM251 (3 mg/kg/day s.c.) vs.
Cremophor-Vehicle, #P < 0.05 vs. Taxol-Vehicle, ϕP < 0.05 Taxol-AM630
(3 mg/kg/day s.c.) and Taxol-AM251 (3 mg/kg/day s.c.) vs. Taxol-Vehicle
and Cremophor-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett
and Tukey post-hoc tests). N = 10–18 per group.
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ery. The high dose of WIN55,212-2 (1 mg/kg/day s.c.)
failed to fully suppress development of paclitaxel-inducedcold allodynia. However, animals in this group nonetheless
showed protection against cold allodynia relative to
paclitaxel-vehicle treated animals at some observation
intervals (i.e., days 11 and 21; P < 0.001).
Anti-allodynic effects of the CB2-preferring agonist AM1710
AM1710 (3.2 mg/kg/day s.c.) suppressed development of
paclitaxel-induced cold allodynia (F4,59 = 14.299, P < 0.001;
P < 0.05 for each comparison) over the time course of drug
delivery (F20,295 = 6.871, P < 0.001; P < 0.05 for each com-
parison; Figure 2f). Lower doses of AM1710 (0.32 and
0.032 mg/kg/day s.c.) had a shorter duration of action;
suppression of cold allodynia was only observed until day
11 (P < 0.05 for each comparison).
Comparison of anti-allodynic efficacy of AM1710 and
WIN55,212-2
We compared the anti-allodynic efficacy of the maximally
efficacious doses of WIN55,212-2 (0.5 mg/kg/day s.c.) and
AM1710 (3.2 mg/kg/day s.c.) under analogous conditions
(Figure 4). Both WIN55,212-2 (0.5 mg/kg/day s.c.) and
AM1710 (3.2 mg/kg/day s.c.) elevated mechanical with-
drawal thresholds in paclitaxel-treated relative to cremo-
phor-vehicle treated rats (F5,66 = 66.292, P < 0.001; P < 0.01
for each comparison; Figure 4a) from day 4 through the final
test day corresponding to drug delivery (F60,792 = 4.888,
P < 0.001; P < 0.05 for each comparison). WIN55,212-2
(0.5 mg/kg/day s.c.) normalized mechanical withdrawal
thresholds in paclitaxel-treated groups with two exceptions;
a transient drop in threshold on days 8 and 16 was
observed relative to the cremophor-vehicle group (P < 0.05
for each comparison). By contrast, AM1710 (3.2 mg/kg/
day s.c.) effectively normalized mechanical thresholds
in paclitaxel-treated animals to those observed in the
cremophor-vehicle group. WIN55,212-2 and AM1710
suppressed development of paclitaxel-induced cold allody-
nia with similar efficacy (F5,66 = 12.365, P < 0.001; P < 0.05
for each comparison; Figure 4b) over the time course
(F25,330 = 6.892, P < 0.001). Neither agonist produced
antinociception to either mechanical or cold stimulation




Pharmacological specificity of WIN55,212-2-medi-
ated anti-allodynia Simultaneous infusion of AM251
(3 mg/kg/day s.c.) suppressed anti-allodynic effects of
WIN55,212-2 (0.5 mg/kg/day s.c.) (F4,57 = 38.335, P <
0.001; Figure 5a) beginning on day 6 and lasting through
the final test day (day 20) corresponding to active drug de-
livery (F48, 684 = 4.112, P < 0.001; P < 0.05 for each com-





















































-7-6 -10 2 4 5 6 11 17 21
### ###
###
Taxol-AM1710 (3.2 mg/kg/day s.c.)
Taxol-WIN55,212-2 (0.5 mg/kg/day s.c.)
Cremophor-Vehicle
Cremophor-AM1710 (3.2 mg/kg/day s.c.)
Cremophor-WIN55,212-2 (0.5 mg/kg/day s.c.)
Taxol-Vehicle
Figure 4 The mixed cannabinoid CB1/CB2 agonist WIN55,212-2 (0.5 mg/kg/day s.c.) and the CB2-preferring agonist, AM1710
(3.2 mg/kg/day s.c.) suppressed the development of both a. mechanical and b. cold allodynia associated with paclitaxel treatment.
No antinociception was observed in cremophor animals treated with either cannabinoid agonist in response to mechanical or cold stimulation.
*P <0.05, **P <0.01,***P <0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P <0.01, ###P <0.001 All conditions vs. Taxol-Vehicle (ANOVA; Dunnett and Tukey
post-hoc tests). N = 10–18 per group.
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Figure 5 Pharmacological specificity of cannabinoid agonist-induced suppression of paclitaxel-induced mechanical and cold allodynia.
a. WIN55,212-2 (0.5 mg/kg/day s.c.)-mediated suppression of paclitaxel-induced mechanical allodynia was dominated by CB1 receptor activation
with some involvement of CB2 receptors. b. The AM1710 (3.2 mg/kg/day s.c.)-induced suppression of paclitaxel-induced mechanical allodynia
was blocked by AM630 (3 mg/kg/day s.c.) but not AM251 (3 mg/kg/day s.c.)). c. Neither AM630 (3 mg/kg/day s.c.) nor AM251 (3 mg/kg/day s.c.)
reliably altered the anti-allodynic effects of WIN55,212-2 (0.5 mg/kg/day s.c.) following acetone application. d. AM630 (3 mg/kg/day s.c.), but not
AM251 (3 mg/kg/day s.c.), blocked the anti-allodynic effects of AM1710 (3.2 mg/kg/day s.c.) to cold stimulation. *P < 0.05, **P < 0.01, ***P < 0.001
vs. Cremophor-Vehicle, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. Taxol-Vehicle, ++P < 0.01 vs. Taxol-Agonist, xxP < 0.01, xxxP < 0.001 Taxol-Agonist and
Taxol-Agonist + AM251 (3) vs. Taxol-Vehicle, tP < 0.05 vs. Taxol-Agonist, Taxol-Agonist + AM630 (3), and Cremophor-Vehicle, ϕP < 0.05, ϕϕP < 0.01,
ϕϕϕP < 0.001 Taxol-Agonist + AM630 (3) and Taxol-Agonist + AM251 (3) vs. Taxol-Agonist, ⊥P < 0.05, ⊥⊥P < 0.01, ⊥⊥⊥P < 0.001 vs. Taxol-Agonist,
Taxol-Agonist + AM251 (3), and Cremophor-Vehicle, δP < 0.05, δδδP <0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630
(3) vs. Taxol-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 10–18 per group.
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allodynic effects of WIN55,212-2 (0.5 mg/kg/day s.c.) (P <
0.05 for each comparison).
Pharmacological specificity of AM1710-mediated
anti-allodynia Simultaneous infusion of AM630 (3 mg/
kg/day s.c.) suppressed anti-allodynic effects of AM1710
(3.2 mg/kg/day s.c.) (F4,61 = 44.885, P < 0.001, Figure 5b)
in paclitaxel-treated rats from days 8 through 20
(F48, 732 = 6.161, P < 0.001, P < 0.05 for each comparison).
By contrast, AM251 (3 mg/kg/day s.c.) failed to block
the anti-allodynic effects of AM1710 (3.2 mg/kg/day
s.c.); thresholds differed reliably from paclitaxel-vehicle
treatment throughout the observation interval (P < 0.05
for each comparison).
Effects of antagonists administered alone Neither
AM630 (3 mg/kg/day s.c.) nor AM251 (3 mg/kg/day)
altered paclitaxel-induced mechanical allodynia relative to
vehicle treatment. Paclitaxel-induced mechanical allodynia
developed equivalently in groups receiving infusions of
either AM630 (3 mg/kg/day s.c.) or AM251 (3 mg/kg/day)
relative to cremophor-vehicle (F3,44 = 58.077, P < 0.001,
P < 0.05 for each comparison; Figure 3b) throughout the
time course (F36,528 = 6.134, P < 0.001).
Cold allodynia
Pharmacological specificity of WIN55,212-2 effects
on cold allodynia WIN55,212-2 (0.5 mg/kg/day s.c.)-
induced suppression of cold allodynia was not reliably
blocked by either AM630 (3 mg/kg/day s.c.) or AM251
(3 mg/kg/day s.c.) (F4,57 = 10.343, P < 0.001; Figure 5c)
(F20,285 = 8.415, P < 0.001, P < 0.05 for each comparison).
Pharmacological specificity of AM1710-mediated anti-
allodynia The AM1710 (3.2 mg/kg/day s.c.)-induced
suppression of cold allodynia was blocked by AM630
(3 mg/kg/day s.c.) (F4,61 = 14.178, P < 0.001, Figure 5d)
but not AM251 (3 mg/kg/day s.c.). This blockade was fully
apparent by days 17 and 21 post-paclitaxel (F20,305 = 8.201,
P < 0.001; P < 0.05 for each comparison). Cold allodynia
developed similarly in paclitaxel-treated rats that re-
ceived AM1710 (3.2 mg/kg/day s.c.) together with
AM251 (3 mg/kg/day s.c.) and AM1710 (3.2 mg/kg/
day s.c.) alone.
Effects of antagonists administered alone Paclitaxel-
treated animals receiving either AM630 (3 mg/kg/day s.c.)
or AM251 (3 mg/kg/day s.c.) developed cold allodynia
(F3,44 = 12.138, P < 0.001; Figure 3c) relative to cremophor-
vehicle control animals (F15,220 = 7.742, P < 0.001, P < 0.05
for each comparison). Taxol-AM251 (3 mg/kg/day s.c.)
animals showed attenuated cold allodynia relative toTaxol-vehicle animals on days 11, 17 and 21 (P < 0.05 for
each comparison) Responsiveness to acetone was, none-
theless, elevated relative to cremophor-vehicle treatment
at each time point (P < 0.05 for each comparison).
Protective effects of WIN55,212-2 and AM1710 following
drug removal
Mechanical allodynia
Paclitaxel produced long-lasting mechanical allodynia in
rats receiving infusions of vehicle relative to cremophor-
vehicle treatment (F75,500 = 2.218, P < 0.01, P < 0.05 for
each comparison; Figure 6a); these effects persisted until
the final test day (day 50). We next examined the pro-
tective effects of WIN55,212-2 and AM1710 following
cessation of drug delivery (Figure 6). WIN55,212-2 (0.5
and 0.1 mg/kg/day s.c., delivered from days −6 through
22) blocked the development of paclitaxel-induced
mechanical allodynia (F3,20 = 48.189, P < 0.001; Figure 6a)
for approximately 11 days following cessation of drug
delivery (F75,500 = 2.218, P < 0.01, P < 0.05 for each compari-
son). Similarly, AM1710 (3.2 mg/kg/day s.c.) protected
against development of paclitaxel-induced mechanical allo-
dynia for 17 days following drug removal (i.e., day 38);
(F3,22 = 41.754, P < 0.001, P < 0.05 for each comparison;
Figure 6b). The low dose of AM1710 (0.032 mg/kg/
day s.c.) also increased paw withdrawal thresholds up
to 17 days following drug removal (P < 0.01 for each
comparison); however, thresholds in this group failed
to differ from the paclitaxel-vehicle condition on sev-
eral days (days 28 and 34), suggesting that mechanical
allodynia was beginning to develop. The high dose
of AM1710 (3.2 mg/kg/day s.c.) produced longer pro-
tection (F75,550 = 2.584, P < 0.001, P < 0.05 for each
comparison; Figure 6c) against mechanical allodynia
development compared to WIN55,212-2 (F3,22 = 69.008,
P < 0.001).
Cold allodynia
Paclitaxel increased responsiveness to acetone in animals
receiving infusions of vehicle throughout the time
course (F30,200 = 3.784, P < 0.001; P < 0.05 for each com-
parison; Figure 7a). WIN55,212-2 (0.5 and 0.1 mg/kg/
day s.c.) suppressed development of paclitaxel-induced
cold allodynia (F3,20 = 12.367, P < 0.001; Figure 7a) up to
12 (day 33) and 18 days (day 39) following cessation of
analgesic drug delivery, respectively. AM1710 (3.2 mg/
kg/day s.c.) suppressed development and postponed
emergence of cold allodynia (F3,22 = 16.132, P < 0.001;
P < 0.05 for each comparison; Figure 7b) for 18 days
following cessation of drug delivery (F30,220 = 4.709,
P < 0.001; P < 0.05 for each comparison). The low dose
of AM1710 (0.032 mg/kg/day s.c.) suppressed cold allo-
dynia through day 33 (P < 0.05 for each comparisons),
indicating a shorter duration of protection relative to
ab
c
Figure 6 Protective effects of WIN55,212-2 and AM1710 on paclitaxel-induced mechanical allodynia following drug removal.
a. WIN55,212-2 (0.5 mg/kg/day s.c.) suppressed paclitaxel-induced mechanical allodynia 11 days (day 32) following drug removal. b. AM1710
(3.2 and 0.032 mg/kg/day s.c.) suppressed hypersensitivity to mechanical stimulation up to 17 days following drug removal (until day 38). c. AM1710
(3.2 mg/kg/day s.c.) produced a longer duration of protection against paclitaxel-induced mechanical allodynia relative to WIN55,212-2 (0.5 mg/
kg/day s.c.). *P < 0.05, **P < 0.01, ***P <0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P <0.01, ###P <0.001 vs. Taxol-Vehicle, ⊥P < 0.05, ⊥⊥P < 0.01, ⊥⊥⊥P < 0.001
Taxol-Agonist (both doses) vs. Taxol-Vehicle, ^P < 0.05 vs. all groups, $P < 0.05, $$$P < 0.001 Taxol-Agonist (both doses) vs. Cremophor-Vehicle, αP < 0.05
Taxol-WIN55,212-2 (0.5 mg/kg/day s.c.) vs. Cremophor-Vehicle, +P < 0.05, ++P < 0.01, Taxol-AM1710 (3.2 mg/kg/day s.c.) and Taxol-WIN55,212-2 (0.5 mg/
kg/day s.c.) vs. Taxol-Vehicle, ϕP < 0.05, ϕϕP <0.01 Taxol-AM1710 (3.2 mg/kg/day s.c.) vs. Taxol-Vehicle, δP < 0.05, δδP < 0.01 Taxol-WIN55,212-2 (0.5 mg/
kg/day s.c.) vs. Taxol-Vehicle, tP < 0.05, ttP < 0.01 Taxol-AM1710 (3.2 mg/kg/day s.c.) and Taxol-WIN55,212-2 (0.5 mg/kg/day s.c.) vs. Cremophor-Vehicle
(ANOVA; Dunnett and Tukey post hoc tests). N = 4–8 per group.
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WIN55,212-2 (0.5 mg/kg/day s.c.) protected against devel-
opment of paclitaxel-induced cold allodynia (F3,22 = 13.216,
P < 0.001, P < 0.05 for each comparison; Figure 7c) over thetime course (F30,220 = 4.439, P < 0.001) The high dose of
AM1710 (3.2 mg/kg/day s.c.) delayed the emergence of




Figure 7 Protective effects of WIN55,212-2 and AM1710 on paclitaxel-induced cold allodynia following drug removal. a. WIN55,212-2
(0.5 and 0.1 mg/kg/day s.c.) suppressed paclitaxel-induced cold allodynia for 12 and 18 days (until day 33 and 39, respectively) following cessation
of drug delivery. b. AM1710 (3.2 mg/kg/day s.c.) suppressed cold allodynia for 18 days following drug removal (until day 39). c. AM1710 (3.2 mg/
kg/day s.c.) produced a longer duration of protection against cold allodynia compared to WIN55,212-2 (0.5 mg/kg/day s.c.). *P < 0.05, **P < 0.01,
***P <0.001 vs. Cremophor-Vehicle, #P < 0.05, ##P <0.01, ###P <0.001 vs. Taxol-Vehicle, ⊥P < 0.05, ⊥⊥P < 0.01 Taxol-Agonist (both doses) vs. Taxol-Vehicle,
ϕP < 0.05, ϕϕP <0.01, ϕϕϕP <0.001 Taxol-AM1710 (3.2 mg/kg/day s.c.) and Taxol-WIN-55,212-2 (0.5 mg/kg/day s.c.) vs. Taxol-Vehicle (ANOVA; Dunnett
and Tukey post-hoc tests). N = 4–8 per group.
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Mechanical allodynia Animals in the Taxol-WIN55,
212-2 (0.5) + AM630 (3) group did not fully develop
mechanical allodynia until day 34 (F4,27 = 41.884, P < 0.001,
P < 0.05 for each comparison; Figure 8a), consistent withthe anti-allodynic efficacy of WIN55,212-2 (0.5 mg/kg/
day s.c.) alone. The AM1710 (3.2 mg/kg/day s.c.) + AM251
(3 mg/kg/day s.c.) group only developed mechanical allody-
nia after day 38 (F4,27 = 25.046, P < 0.001; P < 0.05 for each
comparison; Figure 8b), when protective effects of AM1710
(3.2 mg/kg/day s.c.) alone were no longer apparent.
ab
Figure 8 Pharmacological specificity of cannabinoid-mediated protection against paclitaxel-induced mechanical allodynia following
drug removal. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-mediated anti-allodynia following drug removal was dominated by CB1 receptor activation.
b. The protective effects of AM1710 were blocked by AM630 (3 mg/kg/day s.c.) but not AM251 (3 mg/kg/day s.c.)). *P< 0.05, **P< 0.01, ***P < 0.001 vs.
Cremophor-Vehicle, #P< 0.05, ##P< 0.01, ###P< 0.001 vs. Taxol-Vehicle, xP< 0.05, xxP< 0.01, xxxP< 0.001 Taxol-Agonist and Taxol-Agonist + AM251 (3) vs.
Taxol-Vehicle, ⊥P< 0.05, ⊥⊥P< 0.01, ⊥⊥⊥P< 0.001 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3) and Cremophor-Vehicle, αP< 0.05 Taxol-Agonist + AM630 (3)
vs. Cremophor-Vehicle, βP< 0.05, ββP< 0.01, βββP< 0.001 Taxol-Agonist, Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle,
ϕϕP < 0.01 Taxol-Agonist + AM251 (3), and Taxol-Agonist + AM630 (3) vs. Taxol-Agonist and Cremophor-Vehicle, +P < 0.05, ++P < 0.01 vs. Taxol-Agonist,
ttP < 0.01 Taxol-Agonist + AM251 (3) and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and
Tukey post-hoc tests). N = 6–8 per group.
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AM251 (3 mg/kg/day s.c.) blocked anti-allodynic effects
of WIN55,212-2 (0.5 mg/kg/day s.c.) (F4,27 = 8.965, P < 0.001,
P < 0.05 for each comparison; Figure 9a). Both groups
showed anti-allodynic effects relative to the cremophor-
vehicle group for 18 days following drug removal (i.e.,
up to day 39) (F40,270 = 3.677, P < 0.001; P < 0.05 for each
comparison). The anti-allodynic effects observed in the
WIN55,212-2 blockade conditions outlasted protective
effects observed with WIN55,212-2 (0.5 mg/kg/day s.c.)
administered alone. AM630 (3 mg/kg/day s.c.) blocked
anti-allodynic effects of AM1710 (3.2 mg/kg/day s.c.)
in paclitaxel-treated animals (F4,27 = 12.388, P < 0.001,P < 0.05 for each comparison; Figure 9b) until day 39
(F40,270 = 3.687, P < 0.001). By contrast, the Taxol-AM1710
(3.2 mg/kg/day s.c.) + AM251 (3 mg/kg/day s.c.) group did
not develop cold allodynia until day 45 (P < 0.05 for each
comparison).
Locomotor activity
Total distance traveled did not differ in paclitaxel- or
cremophor-vehicle groups either during (day 19: P > 0.11)
or after (day 31: P > 0.19) chronic drug infusion (Table 1).
Moreover, antagonists did not alter locomotor activity
relative to vehicle during infusion (day 19: P > 0.31). The
combination of WIN55,212-2 (0.5 mg/kg/day s.c.) with
ab
Figure 9 Pharmacological specificity of cannabinoid-mediated protection against paclitaxel-induced cold allodynia following drug
removal. a. WIN55,212-2 (0.5 mg/kg/day s.c.)-induced protection against paclitaxel-induced cold allodynia was not blocked by either a CB1
(AM251, 3 mg/kg/day s.c.) or CB2 (AM630, 3 mg/kg/day s.c.) antagonist. b. Protective anti-allodynic effects associated with AM1710 (3.2 mg/kg/
day s.c.) were mediated via CB2 receptor activation. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Cremophor-Vehicle,
#P < 0.05, ##P < 0.01, ###P < 0.001
vs. Taxol-Vehicle, +P < 0.05, ++P < 0.01 vs. Taxol-Agonist + AM630 (3), xP < 0.05, xxP < 0.01, Taxol-Agonist and Taxol-Agonist + AM251 (3) vs.
Taxol-Vehicle, ⊥P< 0.05 vs. Taxol-Agonist, Taxol-Agonist + AM251 (3) and Cremophor-Vehicle ϕP< 0.05, ϕϕϕP< 0.001 Taxol-Agonist, Taxol-Agonist + AM251
(3) and Taxol-Agonist + AM630 (3) vs. Cremophor-Vehicle, ^^P < 0.01 Taxol-Agonist and Taxol-Agonist + AM630 (3) vs. Taxol-Vehicle, αP < 0.05
Taxol-Agonist + AM630 (3) and Taxol-Agonist + AM251 (3) vs. Cremophor-Vehicle. All doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey
post-hoc tests). N = 6–8 per group.
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traveled (day 19: F5,54 = 2.951, P < 0.05; P < 0.05 for
relevant comparison; Table 1) in paclitaxel-treated
animals relative to cremophor-vehicle animals. After
completion of chronic infusions, paclitaxel-treated ani-
mals that previously received WIN55,212-2 (0.5 mg/
kg/day s.c.) in combination with AM630 (3 mg/kg/
day s.c.) also showed increased distance traveled rela-
tive to WIN55,212-2 (0.5 mg/kg/day s.c.) alone (day
31: F5,30 = 2.769, P < 0.05; P < 0.05 for relevant com-
parison; Table 1). There were no differences in distance
traveled in any AM1710-treated group at any time
point (day 19: P > 0.13; day 31: P > 0.19; Table 1).Lumbar spinal cord mRNA levels of GFAP, CD11b, CB1
and CB2 receptors
To understand the potential molecular targets mediat-
ing the suppression of paclitaxel-induced neuropathy
by WIN55212-2 and AM1710 after cessation of drug
delivery, we examined the mRNA levels of markers
of astrocytes and microglia as well as CB1 and CB2 re-
ceptor mRNA levels. We used RT-PCR to measure the
mRNA levels of the astrocytic marker glial fibrillary
acidic protein (GFAP) and microglial marker cluster
of differentiation molecule 11B (CD11b) (Figure 10a).
RT-PCR analysis revealed a trend towards increased
expression of GFAP (P = 0.059, one-tailed planned
Table 1 Locomotor activity during (Day 19) and after
(Day 31) chronic drug infusions
Group Distance traveled
Day 19 Day 31
Taxol-Vehicle 9108.7 ± 390.5 8369.0 ± 161.7
Cremophor-Vehicle 8186.0 ± 355.6 7843.0 ± 275.2
WIN55,212-2 (0.1) 9652.2 ± 396.2 8986.9 ± 1023.7
WIN55,212-2 (0.5) 9100.4 ± 312.7 7679.7 ± 249.0
WIN-2 (0.5) + AM630 (3) 9827.7 ± 333.9* 9407.0 ± 273.4+
WIN-2 (0.5) + AM251 (3) 8739.3 ± 413.4 8699.2 ± 381.1
AM1710 (0.032) 9482.2 ± 419.9 8263.9 ± 423.6
AM1710 (3.2) 8637.4 ± 412.4 7976.1 ± 469.5
AM1710 (3.2) + AM630 (3) 8562.2 ± 364.2 7577.3 ± 499.3
AM1710 (3.2) + AM251 (3) 8378.1 ± 300.7 7269.8 ± 238.3
AM630 (3) 8016.6 ± 482.3 ‒‒‒‒
AM251 (3) 8442.1 ± 420.1 ‒‒‒‒
Data are mean ± s.e.mean (n = 4-14 per group). All groups received paclitaxel
(Taxol) with the exception of the cremophor group receiving vehicle via chronic
infusion. Statistical comparisons are denoted with line divisions. All divisions
within the table were compared against the cremophor- and paclitaxel-vehicle
control animals. WIN-2, WIN55,212-2. Doses of drugs indicated parenthetically are
in mg/kg/day s.c. *P < 0.05 vs Cremophor-Vehicle, +P < 0.05 vs. Taxol-WIN55,212-2
(0.5 mg/kg/day s.c.) (ANOVA, Tukey Post Hoc).
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paclitaxel- relative to cremophor-vehicle controls on day
22. No alterations in CD11b mRNA levels were observed
at the same time point (P = 0.413). Neither infusion of
WIN55,212-2 (0.5 mg/kg/day s.c.) nor AM1710 (3.2 mg/
kg/day s.c.) altered GFAP or CD11b mRNA expression ina
Figure 10 Impact of paclitaxel and long term drug infusions on mRN
lumbar spinal cord. a. Paclitaxel marginally altered long term expression o
lumbar spinal cord (L4-L6) tissue samples relative to cremophor conditions
kg/day s.c.) and the CB2-preferring agonist AM1710 (3.2 mg/kg/day s.c.) did
mRNA expression in the same tissues. Transcriptional regulation of CB1 and
day s.c.). +P = 0.059 vs. cremophor-vehicle (planned comparison one-tailed
(0.5 mg/kg/day s.c.), # P < 0.05 vs. Taxol-Vehicle, Cremophor-Vehicle, and Ta
hoc tests). N = 4 per group.paclitaxel-treated animals (day 22; P > 0.122 for each com-
parison; Figure 10a). Cannabinoid receptor activation by
chronic agonists may produce compensatory changes in
receptor levels [16], and pathological pain may alter
expression levels of cannabinoid receptors [24-27]. We,
therefore, measured levels of CB1 and CB2 mRNA after vari-
ous treatments (Figure 10b). Both WIN55,212-2 (0.5 mg/kg/
day s.c.) and AM1710 (3.2 mg/kg/day s.c.) increased mRNA
expression of cannabinoid CB1 (F5,23 = 9.527, P < 0.001)
and CB2 (F5,23 = 15.117, P < 0.001; Figure 10b) receptors
in lumbar spinal cord. These agonist-induced increases in
CB1 and CB2 receptor mRNA expression were blocked
in animals that received concurrent administration of
AM630 (3 mg/kg/day s.c.) (P < 0.05 for each comparison).
Discussion
Prophylactic administration of cannabinoid analgesics
protected against the development of paclitaxel-induced
hypersensitivities to mechanical and cold stimulation in
a preventative fashion. Both the mixed cannabinoid
CB1/CB2 agonist WIN55,212-2 and the CB2 agonist
AM1710 blocked development of paclitaxel-induced
mechanical and cold allodynia. Strikingly, the protective
prophylactic effects of both WIN55,212-2 and AM1710
were preserved following drug removal, with the CB2-
specific agonist providing a longer duration of protection
against allodynia development for both mechanical and
cold modalities. In our study, paclitaxel produced marked
mechanical and cold allodynia but not heat hyperalgesia,
as observed in a different dosing paradigm (cumulative
dose: 4 mg/kg i.p.) [28]. In vehicle (cremophor) treatedb
A levels of astrocytes, microglia, and cannabinoid receptors in
f mRNA markers of astrocytes (GFAP) but not microglia (CD11b) in
. Chronic infusions of the mixed CB1/CB2 agonist WIN55,212-2 (0.5 mg/
not alter either GFAP or CD11b b. but increased both CB1 and CB2
CB2 mRNAs were blocked by the CB2 antagonist AM630 (3 mg/kg/
t-test), **P < 0.01, ***P < 0.001, vs. all groups except Taxol-WIN55,212-2
xol-WIN55,212-2 (0.5) + AM630 (3) (ANOVA; Dunnett and Tukey post
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also failed to produce antinociception, suggesting that can-
nabinoids were anti-allodynic rather than analgesic under
these conditions.
Prophylactic WIN55,212-2 suppresses paclitaxel-induced
mechanical and cold allodynia
WIN55,212-2 (0.5 and 0.1 mg/kg/day s.c.) suppressed
the development of paclitaxel-induced mechanical and
cold allodynia both during drug delivery and following
drug removal. Our study is the first to evaluate duration of
efficacy, dose response, and pharmacological specificity of
prophylactic WIN55,212-2. Anti-allodynic effects of both
doses were present 11 (mechanical) and 12 (cold) days fol-
lowing cessation of drug delivery. WIN55,212-2 (0.5 mg/
kg/day s.c.)-induced suppression of mechanical hyper-
sensitivity was dominated by CB1 receptor activation
because anti-allodynic efficacy was blocked by AM251. The
CB2 antagonist AM630 (3 mg/kg/day s.c.) prevented
anti-allodynic efficacy of AM1710 but failed to elimin-
ate WIN55,212-2-mediated anti-allodynia. Interestingly,
blockade of WIN55,212-2-mediated anti-allodynic effects
to cold was not achieved with either antagonist. However,
the same antagonist infusion conditions blocked either
WIN55,212-2 mediated suppression of mechanical allody-
nia (AM251) or AM1710-mediated suppression of both
mechanical and cold allodynia (AM630), documenting
efficacy of antagonist infusion conditions employed here.
We could find only one report of WIN55,212-2-induced
suppression of cold allodynia in a neuropathic pain model
(spinal nerve ligation) where pharmacological specificity
was assessed; anti-allodynic effects were blocked by a CB1
(SR141716a) but not a CB2 (SR144528) antagonist [29].
Blockade of both CB1 and CB2 receptors may be required
to fully prevent anti-allodynic effects of WIN55,212-2.
However, limitations in compound solubility prohibited
co-administration of both antagonists in one pump.
Few studies have examined cannabinoid-mediated
modulation of cold allodynia and/or its development in
neuropathic pain models and more work is necessary
to determine functional contributions of each receptor.
WIN55,212-2 (0.5 mg/kg/day s.c.) treatment increased
both CB1 and CB2 receptor mRNA expression within
lumbar spinal cord of paclitaxel-treated animals on day
22, an effect blocked by concurrent AM630 (3 mg/kg/
day s.c.) treatment. WIN55,212-2 also ameliorates estab-
lished paclitaxel-induced nociception [13] and repeated
administration (1 mg/kg i.p. × 14 days) prevents nocicep-
tion development during drug delivery [11].
Prophylactic AM1710 suppresses paclitaxel-induced
mechanical and cold allodynia
Strikingly, doses of AM1710 as low as 0.032 mg/kg/day
blocked the development of paclitaxel-induced allodyniain our study and these effects were preserved for approxi-
mately three weeks following cessation of drug delivery.
Prophylactic AM1710 treatment suppressed development
of both paclitaxel-induced mechanical and cold allody-
nia, with high (3.2 mg/kg/day s.c.) and low (0.032 mg/
kg/day s.c.) doses exhibiting the greatest efficacy. A
similar U-shaped dose response curve was obtained for
thermal antinociception (plantar test) in naive animals
without observable CB1-mediated side effects [30].
Protective effects of prophylactic AM1710 (3.2 mg/kg/
day s.c.) lasted 17–18 days following drug removal and
outlasted the anti-allodynic effects of WIN55,212-2. Unlike
WIN55,212-2, anti-allodynic effects of AM1710 (3.2 mg/
kg/day s.c.) were mediated by CB2 activation only. Our
lab previously demonstrated AM1710-mediated ameli-
oration of allodynia during the maintenance phase of
paclitaxel-induced nociception (day 20) following acute
administration [15]. Four CB2 agonists have been shown
to ameliorate established paclitaxel-induced neuropathic
nociception [14,15,31,32]. Notably, repeated administra-
tion of the CB2 agonist MDA7 (15 mg/kg i.p. × 14 days)
15 min prior to behavioral evaluations also blocked
paclitaxel-induced mechanical allodynia through a
CB2 mechanism during the phase of drug delivery (i.e.,
behavioral effects blocked by AM630 and absent in
CB2
−/− mice) [16].
Long-term alterations in lumbar spinal cord CB1 or CB2
mRNA expression (day 22) were not induced by paclitaxel-
relative to cremophor-treatment in our study by RT-PCR.
However, prophylactic AM1710 (3.2 mg/kg/day s.c.)
increased both CB1 and CB2 mRNA expression, an
effect blocked by concurrent AM630 (3 mg/kg/day s.c.)
administration. By contrast, MDA7 (15 mg/kg i.p. ×
14 days) has been reported to normalize paclitaxel-
induced increases in lumbar spinal cord CB2 receptor
protein [16]. Differences in paclitaxel dosing (cumula-
tive dose: 8 vs. 4 mg/kg i.p.), CB2 agonist (AM1710 vs.
MDA7), route of administration (mini pump vs. once-
daily injections), or protein vs. mRNA analysis could
help account for these differential findings.
Lack of side effects after either WIN55,212-2 or AM1710
treatment
In our study, animals remained in good health and showed
either normal or enhanced weight gain. WIN55,212-2
(0.1 mg/kg/day s.c.) increased weight gain in paclitaxel-
treated rats. CB1 activation can produce both orexigenic
and metabolic effects to promote weight gain [33].
Interestingly, higher doses of WIN55,212-2 (1–2 mg/
kg/day i.p.) failed to attenuate anorexia or weight loss in
animals treated with cisplatin [34].
Activity meter assessments conducted during prophylac-
tic treatment (day 19) and following drug removal (day 31),
failed to reveal major differences between groups. Thus,
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the CB2 agonist was unlikely to nonselectively activate CB1
receptors; no evidence for hypoactivity [35], a cardinal sign
of CB1 activation, was observed. These findings are consist-
ent with the results documenting absence of cardinal signs
of CB1 receptor activation following acute administration of
AM1710 [30].
Potential mechanisms of action for cannabinoid-mediated
suppression of paclitaxel-induced neuropathic
nociception
Glial activation mediates alterations in synaptic transmis-
sion for a number of excitatory and inhibitory mediators
known to be important for the maintenance of neuro-
pathic pain states [36]. Because of the prolonged suppres-
sion of paclitaxel-induced neuropathy after removal of
cannabinoid agonists, we chose to analyze transcriptional
changes in markers of glial activation. GFAP mRNA
expression in lumbar spinal cord on day 22 (i.e., approxi-
mately 24 h after the pump ceased to release drug) showed
a trend toward increased expression in paclitaxel- relative
to cremophor-treated controls, while no change in CD11b
expression was observed. Increases in astrocytic activation
(GFAP) with no corresponding changes in microglial
activation (OX42, Iba1, and phosphorylated p38) were
also recently observed with the same paclitaxel-induced
neuropathy dosing protocol used here [12]. In another
study, paclitaxel failed to produce microglial activation
(% of cremophor-control staining) on day 27 post-
treatment [37]. By contrast, MDA7 and WIN55,212-2
suppressed paclitaxel-induced glial activation (on days
28 and 29 post-treatment, respectively) when immunohis-
tochemical staining for astrocytes (GFAP) and microglia
(CD11b) was compared with naive animals [11], and it
remains unclear whether vehicle or cremophor adminis-
tration alters glial activation [16]. Cremophor can produce
side effects in both clinical use and animal models [38],
and assumptions that it is inert are not appropriate.
Prophylactic treatment with either a mixed CB1/CB2
agonist or a CB2 agonist, while failing to produce robust
alterations in lumbar spinal cord glial expression, in-
creased CB1 and CB2 mRNA expression. This effect was
blocked by CB2 receptor blockade. Upregulation of endo-
cannabinoids and cannabinoid receptors is associated with
several neuropathic pain models (for review see [39]).
However, to our knowledge, very few, if any, studies have
evaluated alterations following prophylactic cannabinoid
treatment. Increased receptor densities could increase the
potency or efficacy of prophylactic cannabinoids in this
model. More work is necessary to determine whether
changes in CB1 and CB2 mRNA levels observed here are
also associated with changes in receptor protein. Alterna-
tively, increased CB1 and CB2 mRNA expression could
reflect compensatory changes in transcription followingchronic agonist-induced downregulation of receptors.
More work is necessary to fully characterize the duration
of these effects and their therapeutic implications.
Translation to the clinic
Our preclinical studies [14,15,17,18] motivated com-
pletion of a pilot clinical trial utilizing Sativex, an oro-
mucosal extract containing Δ9-tetrahydrocannabinol and
cannabidiol, for treatment of chemotherapy-induced
neuropathy. Sativex suppressed established chemotherapy-
induced neuropathic pain in a subset of responders (5 of
18) in this double-blind placebo-controlled crossover pilot
[40], supporting a further evaluation of the clinical viability
of cannabinoid-based pharmacotherapy.
Conclusion
Prophylactic treatment has been tested as a preventive
strategy for paclitaxel-induced neuropathic nociception
with multiple drugs (for review see [41]). Here, we demon-
strate that cannabinoid agonists with different mecha-
nisms of action prevent development of paclitaxel-induced
neuropathic nociception during treatment and appro-
ximately two to three weeks following cessation of drug
delivery. Paclitaxel treatment marginally altered long-term
GFAP mRNA expression in lumbar spinal cord and this
expression was unaffected by prophylactic cannabinoids,
whereas CD11b mRNA expression was unchanged.
Prophylactic treatment with either WIN55,212-2 (0.5 mg/
kg/day s.c.) or AM1710 (3.2 mg/kg/day s.c.) in paclitaxel
animals did, however, increase both CB1 and CB2 recep-
tor mRNA expression, an effect blocked by concurrent
AM630 (3 mg/kg/day s.c.) administration. Some in-
roads have been made toward discovering mechanisms
for cannabinoid-mediated suppression of paclitaxel-
induced neuropathy, but more work is necessary to de-
termine the scope and time course of this complex
interaction. Our study suggests that further clinical
cannabinoid trials [40] for chemotherapy-induced per-




One hundred seventy-six adult male Sprague–Dawley rats
(beginning weight: 300-400 g; Harlan, Indianapolis, IN)
were used in these experiments. All procedures were
approved by the University of Georgia Animal Care and
Use Committee and followed the guidelines for the treat-
ment of animals of the International Association for the
Study of Pain. Animal experiments were conducted in full
compliance with local, national, ethical and regulatory
principles, and local licensing regulations of the Asso-
ciation for Assessment and Accreditation of Laboratory
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animal care and use/ethics committees.
Animals were allowed a minimum of one week habitu-
ation prior to beginning the study. Animals were single
housed and maintained in a temperature (70-72°F ± 4°F)
and humidity (30-70%) controlled facility on a 12 hour
light cycle (lights on: 07:00 and lights off: 19:00). Food
and water was available ad libitum. Following the initial
pilot study (n = 17), all animals with osmotic mini
pumps were allowed nyla bones (BioServe; Frenchtown,
NJ) due to the study duration. Corn cob bedding con-
taining metabolized paclitaxel was treated as chemical
hazard waste and disposed of according to appropriate
institutional guidelines.
Drugs and chemicals
Paclitaxel (Taxol) was obtained from Tecoland (Edison,
NJ). Polyethylene Glycol 400 (PEG 400) was purchased
from VWR International (West Chester, PA). Acetone
was purchased from J.T. Baker (Phillipsburg, NJ). Cremo-
phor EL, Dimethyl Sulfoxide (DMSO), and WIN55,212-2
((R)-(+)-[2,3-Dihydro-5-methyl-3[(4-morpholinyl)methyl]
pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)metha
none mesylate salt) were obtained from Sigma Aldrich
(St. Louis, MO). AM1710 (3-(1’,1’-dimethylheptyl)-1-
hydroxy-9-methoxy-6H-benzo[c]chromene-6-one), AM251
(N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-
4-methyl-1H-pyrazole-3-carboxamide), and AM630 (6-
Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]
(4-methoxyphenyl)methanone (Iodopravadoline) were syn
thesized in the Center for Drug Discovery by one of the
authors (by GT, VKV, and AZ respectively). Rat subjects
received paclitaxel dissolved as previously described [42],
administered in a volume of 1 ml/kg. Briefly, paclitaxel
was dissolved in a 1:2 ratio of working stock (1:1 ratio of
cremophor EL and 95% ethanol) to saline. AM1710,
WIN55,212-2, AM251, and AM630 were dissolved in a
vehicle of DMSO:PEG 400 in a 1:1 ratio. The selected
vehicle was the most compatible for dissolving cannabi-
noids to be used in Alzet osmotic mini pumps with no
reported adverse side effects [43-45].
General experimental methods
In an initial study, animals were evaluated for development
of paclitaxel-induced behavioral sensitization to mech-
anical and heat stimulation. Responsiveness to different
modalities of cutaneous stimulation was assessed on
alternate days to avoid sensitization. All subsequent studies
used animals surgically implanted with osmotic mini
pumps. Baseline assessments of withdrawal thresholds
to mechanical and cold (acetone drops) stimulation of
the hind paw occurred 48 h (day −8) and 24 h (day −7)
prior to surgery, respectively. Osmotic mini pumps
(Alzet model 2ML4, Cupertino, CA) were implantedsubcutaneously through an incision between the scapu-
lae. Responsiveness to mechanical and cold stimulation
was reassessed post-surgery (i.e., after pump implant-
ation but within 48 h prior to initiation (on day 0) of
paclitaxel dosing). Animals were weighed on all testing
and surgical/sacrifice dates. A subset of animals was
sacrificed via live decapitation (day 22) to extract lumbar
spinal cords. Certain groups (e.g., antagonist alone condi-
tions, submaximal doses of agonists, cremophor-agonist
groups) were only tested through day 22. Osmotic mini
pumps were removed in all remaining animals (day 22),
and following a short recovery period, responses to mech-
anical and cold stimulation were reassessed until day 51
post-paclitaxel.
Drug doses were estimated based on the peak osmotic
mini pump performance reported by the manufacturer
(2.5 μl/hr) and an average rat weight of 375 grams. A small
percentage of animals (4.2%) presented with edema
around the pump site (seromas). Alzet reports this side
effect in < 5% of animals. Treatment for these animals
was supervised by the attending veterinarian and con-
sisted of draining fluid every 3 days, or as needed. Six
animals (3.6%) were re-sutured following surgery. One
of the six animals developed an infection and was
treated (from days 16–22) with daily injections of an
antibiotic (Enrofloxacin 4.5 mg/ml, 0.4 cc s.c., 2× daily)
and sterile water (1 cc s.c., 1× daily) as prescribed by
the staff veterinarian. One animal died during the first
paclitaxel injection and this animal was excluded from
all analyses.
Behavioral measurements, surgeries, chemotherapeutic
treatment, and tissue removal were performed by a sin-
gle experimenter (EJR). Coded testing sheets were used
to preserve blinding. Behavioral testing was performed
in the presence of a white noise generator to mask extra-
neous noise.
Surgical implantation and removal of osmotic mini
pumps
Osmotic mini pumps were implanted under isoflurane
anesthesia (Isoflo®, Abbott Laboratories, Chicago, IL).
The osmotic mini pump was inserted through a surgical
incision made between the scapulae; incisions were su-
tured closed. In the instances where two pumps were
implanted (i.e., agonist and antagonist co-administration
conditions), pumps were placed in the same pocket. The
Alzet model 2ML4 pump has an approximate 2 ml res-
ervoir that releases a preloaded drug or vehicle at a rate
of 2.5 ul/hr for approximately 28 days. The pump begins
to release the preloaded drug approximately 4–6 hours
after implantation; the flow rate is not subject to variations
in body temperature. Osmotic mini pumps were weighed
before and after being filled with drug or vehicle. The dif-
ference of these two values provided an approximate
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(days −5 through −3) to recover from surgery before test-
ing resumed. Animals were either sacrificed or underwent
surgery on day 22 to remove pumps; this time point corre-
sponds to the 29th day following pump implantation,
at which point the pump should have released its
contents. Following pump removal, the residual pump
volume was estimated by withdrawing the remaining
fluid within the pump reservoir. Animals that under-
went surgical removal of osmotic mini pumps were
allowed three days of recovery (days 23–25) prior to
resumption of behavioral testing.
Induction of paclitaxel-induced neuropathic nociception
Rats received four once daily intraperitoneal (i.p.) in-
jections of either paclitaxel (2 mg/kg/day i.p.; cumula-
tive dose of 8 mg/kg i.p.) or cremophor: ethanol: saline
vehicle (1 ml/kg/day i.p.), administered on alternate
days (days 0, 2, 4, and 6) as described previously [28].
Behavioral testing was always performed prior to pacli-
taxel/vehicle administration.
Assessment of paw withdrawal latencies to heat
stimulation
Paw withdrawal latencies to radiant heat were measured
in duplicate for each paw using the Hargreaves test [46]
and a commercially available plantar stimulation unit
(IITC model 336; Woodland Hills, CA). Rats were placed
underneath inverted plastic cages positioned on an ele-
vated glass platform and allowed a minimum of 20 min to
habituate prior to testing. Radiant heat was presented to
the hind paw midplantar region through the floor of the
glass platform. The intensity of the heat source was
adjusted such that an average baseline latency of ap-
proximately 20 sec was achieved [47]. Stimulation was
terminated upon paw withdrawal or after 40 s to pre-
vent tissue damage. Approximately 4 minute interstim-
ulation intervals were allowed between tests. Thermal
withdrawal latencies were evaluated before (day 0) and
on days 2, 6, 10, 14 and 18 following initiation of pacli-
taxel dosing. The same animals were tested for the de-
velopment of mechanical allodynia. Baseline responses
to mechanical stimulation (methodology below) were
measured (on day 0) before baseline responses to ther-
mal stimulation. A minimum of 1 hour was allowed to
elapse between baseline measurements.
Assessment of mechanical withdrawal thresholds
Mechanical withdrawal thresholds were assessed using a
digital Electrovonfrey Anesthesiometer (IITC model Alemo
2390–5; Woodland Hills, CA) equipped with a rigid tip.
Rats were placed underneath inverted plastic cages posi-
tioned on an elevated mesh platform and allowed a 20 min
habituation period prior to testing. Stimulation was appliedto the hind paw midplantar region through the floor of a
mesh platform. Mechanical stimulation was terminated
upon paw withdrawal; consequently, no upper threshold
limit was set for termination of a trial. Two thresholds were
taken for each paw. Approximately 2 minute interstimula-
tion intervals were allowed between tests. Mechanical with-
drawal thresholds were measured on days 0, 4, 8, 12, 16
and 20 for animals that did not receive osmotic mini
pumps (Figure 1). Mechanical withdrawal thresholds were
measured every 2–6 days (i.e., days −8, −2, 0, 2, 4, 6, 8, 10,
12, 14, 16, 18, and 20) for all animals that received osmotic
mini pumps. A subset of osmotic mini pump animals were
tested until day 50 (testing continued with the following
schedule: days 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48,
and 50).
Assessment of cold allodynia
Cold allodynia was assessed using acetone drops applied
to the hind paw midplantar surface as previously de-
scribed [15,48]. Rats were placed underneath inverted
plastic cages positioned on an elevated mesh platform
and allowed a 20 min habituation period prior to testing.
Acetone was loaded into a one cc syringe barrel with no
needle tip. One drop of acetone (approximately 20 μl)
was applied through the mesh platform onto the hind
paw midplantar surface. Care was taken to gently apply
the bubble of acetone to the skin without inducing
mechanical stimulation by syringe barrel contact with
the paw.
Paw withdrawal was recorded as a binary response
(presence or absence) and was frequently accompanied
by nocifensive behaviors (e.g., rapid flicking of the paw,
chattering, biting, and/or licking of the paw). These
nocifensive behaviors were recorded as duration of acet-
one response. Five measurements were taken for each
paw. Testing order alternated between paws (i.e., right,
left). No cut-off latency was enforced. Approximately
2 min interstimulation intervals were allowed between
testing of right and left paws. A minimum interstimula-
tion interval of 5 min was allowed between testing each
pair of paws (right and left). Cold allodynia testing took
place on days −7, −1, 5, 11, 17 and 21 for all animals
with osmotic mini pumps. Five days were allowed be-
tween assessments of cold allodynia to avoid hypersensi-
tivity with one exception. Animals were tested on day 21
because osmotic mini pumps would purportedly still be
releasing drug (i.e., 28 days following pump implant-
ation). A subset of animals was tested to day 51 (i.e.,
testing for these animals continued with the following
schedule: days 27, 33, 39, 45, and 51).
Locomotor activity
Total distance traveled (cm) was assessed using an activity
monitor chamber (Coulbourn Instruments, Whitehall, PA)
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ened room and red light was used to provide illumination.
Tracking beams were positioned 2.54 cm apart giving
1.27 cm in spatial resolution. Activity was automatically
measured by computerized analysis of photobeam inter-
rupts (TruScan 2.0; Coulbourn Instruments, Whitehall,
PA). Animals were allowed a minimum of 15 minutes to
habituate to the room prior to being placed undisturbed in
the activity meter for 15 min. Chlorhexidine was used to
clean the activity meter after each animal. Activity meter
assessment took place both during (day 19) and following
termination (day 31) of drug delivery in a subset of animals
that received chronic infusions.
Prophylactic drug groups
Animals were randomly assigned to drug treatments.
Animals assigned to the paclitaxel condition received pumps
filled with the mixed CB1/CB2 agonist WIN55,212-2 (1, 0.5,
or 0.1 mg/kg/day s.c., n = 8–10 per group), the CB2-pre-
ferring agonist AM1710 (3.2, 0.32, or 0.032 mg/kg/day s.c.,
n = 8–14 per group), vehicle (DMSO:PEG 400, n = 14),
or saline (n = 4). Animals assigned to the cremophor-
vehicle control condition received pumps filled with
either WIN55,212-2 (0.5 mg/kg/day s.c., n = 8), AM1710
(3.2 mg/kg/day s.c., n = 8), vehicle (DMSO:PEG 400, n = 10),
or saline (n = 4).
Pharmacological specificity was assessed in paclitaxel-
treated animals implanted concurrently with two osmotic
mini pumps. One pump contained an antagonist (either
AM251 (3 mg/kg/day s.c.) or AM630 (3 mg/kg/day s.c.))
and the other pump contained an agonist (either WIN55,
212-2 (0.5 mg/kg/day s.c., n = 10 per group) or AM1710
(3.2 mg/kg/day s.c., n = 10 per group)). Separate groups
of paclitaxel-treated animals received pumps filled
with either AM251 (3 mg/kg/day s.c., n = 8) or AM630
(3 mg/kg/day s.c., n = 8).
Quantification of lumbar spinal cord mRNA
Real time RT-PCR was used to quantify mRNA levels
in lumbar spinal cords removed from animals sacrificed
on day 22. Methods are described previously [49]. RNA
from paclitaxel-treated animals that received vehicle,
WIN55,212-2 (0.5 mg/kg/day), WIN55,212-2 (0.5 mg/
kg/day) + AM630 (3 mg/kg/day), AM1710 (3.2 mg/kg/
day), AM1710 (3.2 mg/kg/day) + AM630 (3 mg/kg/day), or
from cremophor-vehicle-treated animals (n = 4 per group)
were extracted using a TRIzol (Invitrogen)/RNeasy
(Qiagen) hybrid protocol according to manufacturer’s
instructions. Purified RNA from each sample was then
treated with DNase 1. Expression levels of GFAP, CD11b,
CB1, and CB2 mRNAs were quantified using one step
RT-PCR in a Mastercycler ep realplex RT-PCR machine
(Eppendorf North America Inc., Hauppauge, NY) using
PowerSYBR green PCR kit (Applied Biosystems, Carlsbad,CA). GAPDH (glyceraldehyde-3-phosphate dehydrogen-
ase) was used as internal standard to normalize mRNA
levels. Primers used were as follows: rat GAPDH (sense:
5′-ATGACTCTACCCACGGCAAG-3′, anti-sense: 5′CA
TACTCTGCACCAGCATCTC-3′); rat GFAP (sense: 5′-
GAGTCCACAACCATCCTTCTGAG-3′, anti-sense: 5′-
ACACCAGGCTGCTTGAACAC-3′); rat CD11b (sense:
5′-CTGGGAGATGTGAATGGAG-3′, anti-sense: 5′-AC
TGATGCTGGCTACTGATG-3′); rat CB1 (sense: 5′-CT
ACTGGTGCTGTGTGTCATC-3′ and anti-sense: 5′-GC
TGTCTTTACGGTGGAATAC-3′); rat CB2 (sense: 5′-GC
AGCCTGCTGCTGACCGCTG-3′, anti-sense: 5′-TGCTT
TCCAGAGGACATACCC-3′).Statistical analyses
Percentage of paw withdrawals from acetone application
to the hind paws was calculated using the following
formula: ((Total number of paw withdrawals) * 100)/10.
Data were analyzed using analysis of variance (ANOVA)
for repeated measures, one-way ANOVA, or planned
comparison t-test as appropriate. SPSS 19.0 (SPSS
Incorporated, Chicago, IL, USA) statistical software
was employed. The Greenhouse-Geisser correction was
applied to all repeated factors where the epsilon value
from Mauchly’s Test of Sphericity was < 0.75 and signifi-
cance level was P < 0.05. Degrees of freedom reported for
interaction terms of repeated factors are uncorrected
values in cases where the Greenhouse-Geisser correction
factor was applied. Post-hoc comparisons between the
primary control group (paclitaxel-vehicle) and other
experimental groups were performed using the Dunnett
test (2-sided). Post-hoc comparisons between different
experimental groups were also performed to assess
dose–response relationships and pharmacological speci-
ficity using the Tukey test. Levene’s test for homosce-
dasticity was applied to all planned comparison t-tests.
P < 0.05 was considered statistically significant.Abbreviations
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